The homocysteine paradox

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 28, Issue 6, 2008, Pages 1031-1033

  Rodionov, Roman N ^a   Lentz, Steven R ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE DERIVATIVE; BETAINE; CYANOCOBALAMIN; CYSTATIN C; FOLIC ACID; HOMOCYSTEINE; PYRIDOXINE; ARGININE; CYSTATIN; DRUG DERIVATIVE; N,N DIMETHYLARGININE; N,N-DIMETHYLARGININE;

AMINO ACID BLOOD LEVEL; CARDIOVASCULAR RISK; CLINICAL TRIAL; DISEASE ASSOCIATION; EDITORIAL; HUMAN; HYPERHOMOCYSTEINEMIA; KIDNEY DISEASE; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RISK REDUCTION; VASCULAR DISEASE; VASCULAR ENDOTHELIUM; VITAMIN SUPPLEMENTATION; ANIMAL; BLOOD; CARDIOVASCULAR DISEASE; DISEASE MODEL; GLOMERULUS FILTRATION RATE; NOTE; PHYSIOLOGY; RISK FACTOR;

ANIMALS; ARGININE; CARDIOVASCULAR DISEASES; CYSTATINS; DISEASE MODELS, ANIMAL; FOLIC ACID; GLOMERULAR FILTRATION RATE; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; KIDNEY DISEASES; RISK FACTORS; VITAMIN B 12; VITAMIN B 6;

EID: 44849093522     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATVBAHA.108.164830     Document Type: Editorial

References (20)

1. Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA. 2002;288:2015-2022.
2. den Heijer M, Lewington S, Clarke R. Homocysteine, MTHFR and risk of venous thrombosis: a meta-analysis of published epidemiological studies. J Thromb Haemost. 2005;3:292-299.
3. Dayal S, Lentz SR. Role of redox reactions in the vascular phenotype of hyperhomocysteinemic animals. Antioxid Redox Signal. 2007;9: 1899-1909.
4. Toole JF, Malinow MR, Chambiess LE, Spence ID, Pettigrew LC, Howard VJ, Sides EG, Wang CH, Stampfer M. Lowering homocysteine in patients with, ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA. 2004;291:565-575.
5. Lonn E, Yusuf S, Arnold MJ, Sheridan P, Pogue J, Micks M, McQueen MJ, Probstfield J, Fodor G, Held C, Genest J Jr. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med. 2006;354:1567-1577.
6. Bonaa KH, Njolstad I, Ueland PM, Schirmer H, Tverdal A, Steigen T, Wang H, Nordrehaug JE, Arnesen E, Rasmussen K. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med. 2006;354:1578-1588.
7. den Heijer M, Willems HP, Blom HJ, Gerrits WB, Cattaneo M, Eichinger S, Rosendaal FR, Bos GM. Homocysteine lowering by B vitamins and the secondary prevention of deqp vein thrombosis and pulmonary embolism: a randomized, placeto-controlled, double-blind trial. Blood. 2007;109:139-144.
8. Jamison RL, Hartigan P, Kaufman JS, Goldfarb DS, Warren SR, Guarino PD, Gaziano JM. Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial. JAMA. 2007;298:1163-1170.
9. McCully KS. Homocysteine, vitamins, and vascular disease prevention. Am J Clin Nutr. 2007;86:1563S-8S.
10. Mndd SH, Skovby F, Levy HL, Pettigrew KD, Wilcken B, Pyeritz RE, Andria G, Boers GHJ, Bromberg IL, Cerone R, Fowler B, Grobe H, Schmidt H, Schweitzer L. The natural history of homocystinuria due to cystathionine β-synlhase deficiency. Am J Hum Genet. 1985;37:1-31.
11. Yap S, Boers GH, Wilcken B, Wilcken DE, Brenton DP, Lee PJ, Walter JH, Howard PM, Naughten ER. Vascular outcome in patients with homo-cystinuria due to cystathionine beta-synthase deficiency treated chronically: a multicenter observational study. Arterioscl Thromb Vasc Biol. 2001;21:2080-2085.
12. Clarke R, Armitage J, Lewington S, Collins R. Homocysteine-lowering trials for prevention of vascular disease: protocol for a collaborative meta-analysis. Clin Chem Lab Med. 2007;45:1575-1581.
13. Yang Q, Botto LD, Erickson JD, Berry RJ, Sambell C, Johansen H, Friedman JM. Improvement in stroke mortality in Canada and the United States, 1990 to 2002. Circulation. 2006;113:1335-1343.
14. Wang X, Qin X, Demirtas H, Li J, Mao G, Huo Y, Sun N, Liu L, Xu X. Efficacy of folic acid supplementation in stroke prevention: a meta-analysis. Lancet. 2007;369:1876-1882.
15. Schiffrin EL, Lipman ML, Mann JF. Chronic kidney disease: effects on the cardiovascular system. Circulation. 2007;116:85-97.
16. Friedman AN, Bostom AG, Selhub J, Levey AS, Rosenberg IH. The kidney and. homocysteine metabolism. J Am Soc Nephrol. 2001;12: 2181-2189.
17. Bostom AG, Gohh RY, Bausserman L, Hakas D, Jacques PF, Selhub J, Dworkin L, Rosenberg IH. Serum cystatin C as a determinant of fasting total homocysteine levels in renal transplant recipients with, a normal serum creatinine. J Am Soc Nephrol. 1999;10:164-166.
18. Bostom AG. Homocysteine: "Expensive creatinine" or important, modifiable risk factor for arteriosclerotic outcomes in renal transplant recipients? J Am Soc Nephrol. 2000;11:149-151.
19. The VITATOPS (Vitamins to Prevent. Stroke) Trial: rationale and. design of an international, large, simple, randomised trial of homocysteine-lowering multivitamin therapy in patients with, recent transient ischaemic attack or stroke. Cerebrovasc Dis. 2002; 13: 120-126.
20. van GC, Nanayakkara PW, Stehouwer CD. Homocysteine and asymmetric dimethylarginine (ADMA): biochemically linked, but differently related to vascular disease in chronic kidney disease. Clin Chem Lab Med. 2007;45:1683-1687.